Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor

American Journal of Neuroradiology

Volumn 25, Issue 5, 2004, Pages 830-834

  Fortin, David ^a   Salamé, Joseph A ^a   Desjardins, Annick ^a   Benko, Andrew ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b CHUS ^*

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MANNITOL; METHOTREXATE; PLATINUM; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; B CELL LYMPHOMA; BLOOD BRAIN BARRIER; BRAIN TUMOR; CELL INFILTRATION; CHEMOTHERAPY; CLINICAL TRIAL; DIPLOPIA; DRUG DELIVERY SYSTEM; EOSINOPHIL; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; FEMALE; HUMAN; INFLAMMATION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; ORBIT; ORBIT PSEUDOTUMOR; OSMOTIC STRESS; PATHOLOGICAL ANATOMY; PHASE 2 CLINICAL TRIAL; PLASMA CELL; POSTOPERATIVE COMPLICATION; SOFT TISSUE; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; CARBOPLATIN; CAROTID ARTERIES; FEMALE; GRANULOMA, PLASMA CELL, ORBITAL; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; OSMOSIS; RECURRENCE;

EID: 2442635495     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Miller NR, Newman NJ. Walsh & Hoyst's clinical neuro-ophthalmology: the essentials. 5th edition. Philadelphia: Lippincott, Williams and Wilkins; 1998:677-679
2. Lee MS, Lessell S. Orbital myositis posing as cluster headache. Arch Neurol 2002;59:635-636
3. Maurer I, Zierz SJ. Recurrent orbital myositis: report of a familial incidence. Arch Neurol 1999;56:1407-1409
4. Nabili S, McCarey DW, Browne B, Capell HA. A case of orbital myositis associated with rheumatoid arthritis. Ann Rheum Dis 2002;61:938-939
5. Pollard Z. Acute rectus muscle palsy in children as a result of orbital myositis. J Pediatr 1996;128:230-233
6. Kupersmith MJ, Frohman LP, Choi IS, et al. Visual system toxicity following intra-arterial chemotherapy. Neurology 1988;38:284-289
7. Margo CE, Murtagh FR. Ocular and orbital toxicity after intracarotid cisplatin therapy. Am J Ophthalmol 1993;116:508-509
8. Wu HM, Lee AG, Lehane DE et al. Ocular and orbital complications of intraarterial cisplatin. J Neuroophthalmol 1997;17:195-198
9. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000; 59(Suppl)4:S19-S27
10. Selvaratnam G, Philips RH, Mohamed AK, Radzi A. Adverse effects of cytotoxics-platinum agents. Adverse Drug React Toxicol Rev 1997;16:171-197
11. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17: 409-422
12. Yung WKA, Mechitler Laszlo, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991;9:860-864
13. Twelves CJ, Ash CM, Miles DW, et al. Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma. Cancer Chemother Pharmacol 1991;27:481-483
14. Warnick RE, Prados MD, Mack EE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neuro-Oncol 1994;19:69-74
15. Lunardi P, Farah JO, Mastronardi I, et al. Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. Acta Neurochirurgica 1996; 138:215-220
16. Prados MD, Warnick RE, Mack EE, et al. Intravenous carboplatin for recurrent gliomas. Am J Clin Oncol 1996;19:609-612
17. Friedman HS, Shelley L, Rasheed K, Friedman AH. Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Med Pediatr Oncol 1998;31:16-18
18. Huncharedk M, Kupelnick B, Bishop D. Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat Rev 1998;24:307-316
19. Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 1995;37:17-27
20. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000;88:637-647
21. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998;42:1083-1100
22. Fortin D, McAllister LD, Nesbit G, et al. Unusual cervical spine cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide with osmotic blood brain-barrier disruption in the vertebral artery. AJNR Am J Neuroradiol 1999;20:1794-1802
23. Desjardins A, Boudrias M, Fortin D. Osmotic blood-brain barrier disruption to enhance chemotherapy delivery in the treatment of brain tumors: the Sherbrooke experience. A-07. Can J Neurol Sci 2002;(Suppl 1):S9
24. Fortin D, Neuwelt EA Therapeutic Manipulation of the Blood-Brain Barrier: Neurobase-Neurosurgery. 1st ed. San Diego: Medlink Neurology; 2002
25. Silbergeld DI, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 1997;86:525-531
26. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000;46:51-61